1. Introduction {#s0005}
===============

Community-acquired pneumonia (CAP) is a serious health problem causing high morbidity and mortality worldwide ([@bb0100]). The rates of patients hospitalized due to CAP are increasing, with 22%--42% of adults needing admission to the hospital. In addition, CAP has an associated mortality of 5%--14% in patients requiring hospitalization. Approximately 5% of the patients hospitalized with CAP require admission to an intensive care unit (ICU). In these severe cases mortality rises to 35% ([@bb0085]).

Host individual variability is now recognized as a key factor influencing clinical expression and prognosis of CAP ([@bb0080]). Learning from the successes of using precision medicine in the treatment of cancer, identifying individual phenotypes associated with poor outcome in CAP could help to better understand the pathogenesis of this disease and to improve its treatment ([@bb0125]; [@bb0120]; [@bb0005]). In this regard, Davenport et al., using a transcriptomic analysis, found a gene expression signature (SRS1) which identifies individuals with an immunosuppressed phenotype and higher 14-day mortality within a cohort of patients with sepsis secondary to CAP ([@bb0050]). In addition, new biomarkers such as expression of HLA-DR on monocytes ([@bb0150]), soluble CD14 (presepsin) ([@bb0075]), interleukins ([@bb0115]; [@bb0015]), procalcitonin ([@bb0090]), and mid-regional pro-ADM ([@bb0095]) could help risk assessment in the early stages of the disease. As an alternative to these new sophisticated (and expensive)"omics" and biomarker-based approaches, a simple leukogram has shown potential to be a tool for classifying patients with CAP or sepsis based on their outcomes. The neutrophil/lymphocyte ratio (NLR) has been proposed as a candidate predictor of mortality for hospitalized CAP patients ([@bb0040]). Further, we have demonstrated that patients with septic shock who fail to expand circulating neutrophil counts in their blood present an increased risk of mortality ([@bb0030]).

The objective of the present study was to evaluate the potential role of neutrophil and lymphocyte counts in blood as biomarkers of mortality risk in patients with CAP and no antecedents of immunosuppression. For this purpose, we performed a derivation-validation retrospective study employing two large cohorts of hospitalized patients with this disease.

2. Materials and Methods {#s0010}
========================

2.1. Study Design {#s0015}
-----------------

A derivation-validation retrospective study was performed to evaluate the association between neutrophil and lymphocyte counts at hospital admission and the risk of mortality at 30 days following admission, in patients hospitalized with CAP. The derivation cohort comprised patients recruited in the context of a multi-site study while those of the validation cohort were recruited in the context of a single-site study. Only those patients showing complete data for lymphocyte and neutrophil counts in the first 24 h following admission to the hospitaland the variables "admission to the ward or ICU", and "mortality at 30 days post-admission from hospital" were included in the analysis.

2.2. Patient Selection, Inclusion and Exclusion Criteria {#s0020}
--------------------------------------------------------

### 2.2.1. Multi-Site (Derivation) Cohort {#s0025}

The patients included in this cohort had been admitted to 14 Spanish hospitals (NEUMONAC group), other than the Hospital Clinic (Barcelona). Patients were recruited from January 2012 to June 2015. Inclusion criteria were the presence of (assumed) new pulmonary infiltrate shown by chest radiograph and respiratory signs and symptoms compatible with CAP (cough, expectoration, chest pain, dyspnea, fever, among others). Exclusion criteria were as follows: nursing-home patients and immunosuppression status (human immunodeficiency virus-positive, acute leukemias, myelodysplastic syndromes, myelodysplastic and myeloproliferative syndromes, chronic myeloproliferative syndromes, lymphoproliferative syndromes, monoclonal gammopathies, marrow failure syndromes, primary immunodeficiencies and severe chronic neutropenia, solid-organ transplantation, \> 14 days of treatment with \> 20 mg/day of prednisone or equivalent, and other immunosuppressive drugs).

### 2.2.2. Single-Site (Validation) Cohort {#s0030}

This comprised consecutive patients admitted to the Hospital Clinic, Barcelona, Spain, between January 2005 and December 2015 with a diagnosis of CAP. Pneumonia was defined as an (assumed) new pulmonary infiltrate found on the hospital admission chest radiograph and symptoms and signs of lower respiratory tract infection. Patients with prior immunosuppression were excluded (for example, patients with neutropenia after chemotherapy or bone marrow transplantation, patients with drug-induced immunosuppression as a result of solid-organ transplantation, corticosteroid (\> 10 mg/day) or cytotoxic therapy, and patients with HIV-infection).

### 2.2.3. Other Definitions {#s0035}

In both studies, acute respiratory distress syndrome (ARDS) was identified in the first 24 h after hospital admission by applying the criteria described in the Berlin definition ([@bb0020]). The appropriateness of empiric antibiotic treatment was defined according to multidisciplinary guidelines for the management of CAP ([@bb0140]). Acute renal failure was defined using the criteria developed by the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group ([@bb0025]). Septic shock was defined according to the definition proposed by the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference ([@bb0035]).

2.3. Ethics {#s0040}
-----------

for the multi-site cohort, the Ethics Committee of the coordinating center approved the study (Code: 2011/0512). For the single-site cohort, the Ethics Committee of the Hospital Clinic of Barcelona approved the study (Code: 2009/5451). Given the observational and retrospective nature of the study, informed consent was waived. This study fulfils the standards indicated by the Declaration of Helsinki.

2.4. Leukocyte, Lymphocyte and Neutrophil Quantification {#s0045}
--------------------------------------------------------

This measurement was performed on blood collected in ethylenediaminetetraacetic acid tubes by using the automatic analyzers available in each participating hospital at the central laboratories, under standard operative procedures approved for clinical use. Lymphopenia was considered as a total lymphocyte count \< 1000/mm^3^, following the definition proposed in *Hematology*, 9th ed (Vasu S, Caligiuri MA, 2015).

2.5. Statistical Analysis (Supplementary file 1) {#s0050}
------------------------------------------------

Differences in demographic and clinical characteristics between patient cohorts or sub-groups were assessed using the chi-squared test. The association between lymphocyte, neutrophil counts, C-reactive protein (CRP) levels, and the risk of mortality in the 30 days following hospital admission was evaluated by logistic regression analysis ([@bb0070]). Potential confounding variables were selected by assessing the association between those variables shown in [Table 1](#t0005){ref-type="table"} with mortality. Variables yielding a p value \< 0.1 in the univariate regression analysis were further included in the multivariate analysis as adjusting variables. Final selection of the variables was performed by using the backward stepwise selection method (Likelihood Ratio) (pin \< 0.05, pout \< 0.10). Lymphocyte, neutrophil, and CRP concentrations were transformed to Naeperian log values in order to reach a normal distribution. Those variables showing a Spearman correlation coefficient \> 0.3 with another inclusive variable were excluded from the multivariate analysis ([@bb0065]). The final number for each analysis (excluding the missing values) is shown in [Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"}, [Table 3](#t0015){ref-type="table"}, [Table 4](#t0020){ref-type="table"}, [Table 5](#t0025){ref-type="table"}. The ability of lymphocyte counts to differentiate survivors from non-survivors was assessed by using the area under the receiver operating characteristic curve analysis (AUC). The cut-off for lymphocyte counts regarding mortality prediction was obtained in the derivation cohort by calculating the optimal operating point (OOP) in the AUC, as previously described ([@bb0010]). The OOP was considered the value for which the point on the curve had the minimum distance to the upper left corner (where sensitivity = 1 and specificity = 1). By Pythagoras\' theorem this distance is:$${OOP} = \sqrt{\left( {1 - \text{sensitivity}} \right)^{2} + \left( {1 - \text{specificity}} \right)^{2}}$$Table 1Clinical characteristics of the studied cohorts. Data presented as n (%) or median (interquartile range). Microbiological data were calculated using the number of patients with positive microbiological identification. COPD: Chronic Obstructive Pulmonary Disease; ICU: Intensive care unit, ARDS: Acute Respiratory Distress Syndrome.Table 1CharacteristicsMulti-site (derivation) cohort\
N = 1550Single-site (validation) cohort\
N = 2846P valueN (%)N for each variableN (%)N for each variableDemographic data and treatmentAge (≥ 65 years)926 (59.7)15501948 (68.6)2838\< 0.002Sex male962 (62.1)15501733 (60.9)2846nsCurrent smoking319 (21.9)1456548 (19.5)2813nsAlcohol abuse131 (9.0)1451382 (13.6)2805\< 0.001Pneumococcal vaccine162 (11.9)1352467 (18.7)2496\< 0.001Influenza vaccine572 (40.1)14271204 (48.1)2502\< 0.001Oral steroids72 (4.6)1550127 (4.5)2792nsInhaled steroids364 (23.5)1550567 (20.3)27880.015Antibiotic last month384 (24.8)1550663 (24.7)2686nsComorbidityCardiac disease436 (28.3)1538409 (14.5)2824\< 0.001Chronic renal failure138 (9.0)1529218 (7.7)2817nsLiver disease62 (4.1)1527141 (5.0)2817nsDiabetes mellitus337 (22)1529636 (22.7)2804nsChronic pulmonary disease (COPD/asthma)421 (27.6)15251090 (39.3)2771\< 0.001Neurological disease254 (16.6)1526574 (20.9)27500.001Initial severityInitial ICU admission131 (8.5)1550586 (20.6)2846\< 0.001CURB65 (≥ 3)219 (14.3)1534488 (20.7)2355\< 0.001MicrobiologyKnown microbiology etiology702 (45.3)15501161 (40.8)28460.004Streptococcus pneumoniae435 (62.0)702481 (41.4)1161\< 0.001Legionella pneumophila33 (4.7)70261 (5.3)1161nsPolimicrobial etiology82 (11.7)702153 (13.2)1161nsVirus95 (13.5)702204 (17.6)11610.021Complications and outcomesAppropriate antibiotic1049 (85.8)12232313 (95.8)2414\< 0.001Acute renal failure87 (5.6)1550760 (27.2)2796\< 0.001Pleural effusion95 (6.1)1550400 (14.4)2772\< 0.001Mechanical ventilation95 (6.3)1501301 (13.1)2305\< 0.001ARDS56 (3.6)1550123 (4.6)2667nsSeptic shock65 (4.2)1550158 (5.7)27890.034Mortality at 30 days72 (4.6)1550234 (8.2)2846\< 0.001Table 2Univariate and multivariate regression analysis for mortality risk in the multi-site (derivation) cohort. OR: Odds Ratio; CI: confidence interval.Table 2VariableUnivariateMultivariate\
(N = 1209)ORCI 95%pORCI 95%pCardiac disease2.101.30--3.390.002------Neurological disease2.601.55--4.36\< 0.001------Chronic renal failure3.411.92--6.06\< 0.0012.461.17--5.180.017CURB-65 ≥ 36.353.89--10.37\< 0.0014.132.23--7.65\< 0.001Initial ICU admission3.391.88--6.09\< 0.0012.261.04--4.900.039Apropriate antibiotic treatment0.270.15--0.48\< 0.0010.260.14--0.49\< 0.001Lymphocytes (cell/mm^3^) (Ln)0.570.42--0.78\< 0.0010.660.44--0.980.044Table 3Univariate and Multivariate regression analysis for mortality risk in the single site (validation) cohort. OR: Odds Ratio; CI: confidence interval.Table 3UnivariateMultivariate\
(N = 1878)ORCI 95%pORCI 95%pSmoking\< 0.0010.059 No smoker1----1---- Smoker0.390.25--0.61\< 0.0010.470.25--0.880.019 Ex-smoker0.690.51--0.940.0170.800.53--1.210.29Cardiac disease1.451.02--2.040.038------Chronic renal failure1.831.21--2.780.004------Neurological disease3.642.75--4.82\< 0.0012.411.60--3.63\< 0.001CURB-65 ≥ 33.422.51--4.66\< 0.0012.851.92--4.23\< 0.001ARDS (complication)3.402.15--5.37\< 0.0013.291.78--6.09\< 0.001Respiratory virus0.440.21--0.890.024------Initial ICU admission1.541.14--2.090.0051.911.22--2.990.005Appropriate antibiotic treatment0.340.20--0.57\< 0.0010.410.21--0.800.009Lymphocytes (cell/mm^3^) (Ln)0.920.86--0.980.0080.890.81--0.980.023Table 4Multivariate regression analysis to predict mortality risk in the multi-site (derivation) cohort. OR: Odds Ratio; CI: confidence interval.Table 4VariableMultivariate analysis\
(N = 1209)ORCI 95%pChronic renal failure2.471.18--5.190.017CURB-65 ≥ 33.992.15--7.400.000Initial ICU admission2.221.03--4.800.043Apropriate antibiotic treatment0.270.14--0.500.000\< 724 lymphocyte/mm^3^1.931.06--3.510.031Table 5Multivariate regression analysis to predict mortality risk in the single site (validation) cohort. OR: Odds Ratio; CI: confidence interval.Table 5Multivariate analysis\
(N = 1878)ORCI 95%pSmoking0.043 No smoker1---- Smoker0.460.24--0.860.015 Ex-smoker0.770.51--1.150.20Neurological disease2.361.57--3.54\< 0.001CURB-65 ≥ 32.771.87--4.09\< 0.001ARDS (complication)3.171.71--5.89\< 0.001Initial ICU admission1.721.10--2.700.019Appropriate antibiotic treatment0.420.22--0.810.010\< 724 lymphocytes/mm^3^1.861.28--2.710.001

The ability of this cut-off value to predict 30-day mortality was further evaluated by using multivariate logistic regression analysis in the derivation cohort in a first step and in the validation cohort in a second step. Comparisons between the AUCs were assessed according to the method of DeLong et al. ([@bb0055]). The level of significance was set at 0.05 (2-tailed). All analyses were performed with IBM SPSS Statistics 20.0 (Armonk, New York) and MedCalc 17.8.5 (Ostend, Belgium).

3. Results {#s0055}
==========

3.1. Clinical Characteristics of the Patients ([Table 1](#t0005){ref-type="table"}) {#s0060}
-----------------------------------------------------------------------------------

the derivation cohort comprised 1550 patients, and the validation cohort 2846. The proportion of patients older than 65 years was higher in the validation study. In turn, the proportion of those who had received vaccination against *S. pneumoniae* or *influenza virus* was higher in the validation study. Prevalence of chronic pulmonary disease and neurological disease was also higher in those patients recruited in the validation cohort. Therefore, the symptoms observed in this cohort were in turn more severe, as evidenced by the increased proportion of patients showing a CURB-65 score ≥ 3, of patients requiring admission to the ICU, and finally of patients showing renal failure, pleural effusion, septic shock, and mechanical ventilation as complications during hospitalization. In agreement with this scenario, the frequency of non-survivors in the validation cohort was almost 2-fold greater than that in the derivation cohort, although the majority of the patients in this cohort had received an appropriate antibiotic treatment. Patients in the derivation cohort more frequently showed an antecedent of cardiac disease, and these patients also showed a higher proportion of pneumococcal CAP cases and a lower proportion of viral CAP within those patients with a positive microbiological identification. The mean length of hospitalization was 6 (4--9) days in the derivation study and 8 days (6--12) in the validation study (median, interquartile range). The percentage of patients showing lymphopenia in each cohort was the same, 52% (818 of 1550 patients in the derivation study and 1499 patients of 2846 patients in the validation study). In the derivation study and validation study, respectively, leukocyte counts were similar in both cohorts, median (interquartile range): leucocytes (cells/mm^3^): 13,000 (9200--17,790) vs 12,300 (8400--17,300); neutrophils (cells/mm^3^): 10,823 (7274--15,187) vs 10,126 (6636--14,700); and lymphocytes (cells/mm^3^): 957 (616--1445) vs 950 (578--1440).

3.2. Analysis of Mortality Risk in the 30 days Following Hospital Admission {#s0065}
---------------------------------------------------------------------------

Neutrophil counts were not associated with 30-day mortality in the univariate analysis, neither in the derivation cohort (OR \[95%CI\], p: 0.75 \[0.52--1.09\], 0.135), nor in the validation cohort (0.95 \[0.89--1.02\], 0.170). The same was true for CRP (OR \[95%CI\], p: 1.13 \[0.94--1.36\], 0.194 in the derivation cohort, and in the validation cohort (1.02 \[0.88--1.17\], 0.800). In consequence, these parameters were not evaluated in the multivariate analysis. In contrast, lymphocyte counts were a protective factor against 30-day mortality in both cohorts and in both the univariate and the multivariate analysis ([Table 2](#t0010){ref-type="table"}, [Table 3](#t0015){ref-type="table"}). AUC analysis demonstrated that lymphocyte counts were able to differentiate between survivors and non-survivors at 30 days, although the areas obtained were modest ([Fig. 1](#f0005){ref-type="fig"}).Fig. 1AUROC Analysis of Lymphocyte Concentrations in Blood to Predict Survival at 30-Days Post-Admission.The OOP was identified in the derivation cohort as \< 724 lymphocytes/mm^3^. Sensitivity/Specificity for the OOP were 57%/68% in the derivation cohort and 67%/50% in the validation cohort.Fig. 1

3.3. Derivation and Validation of the Lymphocyte Cut-Off Value to Predict 30-day Mortality {#s0070}
------------------------------------------------------------------------------------------

AUC analysis in the derivation cohort identified 724 lymphocytes/mm^3^ as the best cut-off value for identifying non-survivors ([Fig. 1](#f0005){ref-type="fig"}). Multivariate analysis demonstrated that presenting with lymphocyte counts below 724 lymphocytes/mm^3^constituted an independent risk factor of mortality in the derivation cohort ([Table 4](#t0020){ref-type="table"}). The same result was found in the validation cohort ([Table 5](#t0025){ref-type="table"}). In both cohorts, the ORs adjusted by their respective confounding factors were very similar (1.93 in the derivation cohort and 1.86 in the validation cohort).

3.4. Improvement of the Ability of the CURB-65 Score to Predict Mortality by Addition of Lymphocyte Counts {#s0075}
----------------------------------------------------------------------------------------------------------

Those patients with lymphocyte counts below 724 lymphocytes/mm^3^ were given an extra point in the CURB-65 score, to build the "CURB-65L" score ("L" meaning "lymphocyte"). When an AUROC analysis was performed to compare the ability of CURB-65 to predict mortality against that of the new CURB-65L score, the latter yielded a significantly higher AUC in both the derivation and the validation cohorts, based on the results of the DeLong test ([Fig. 2](#f0010){ref-type="fig"}).Fig. 2Comparison of AUCs of CURB-65 and CURB-65L to Predict 30-Day Mortality: One extra point was added to the CURB-65 score of those patients with lymphocyte counts below 724 cells/mm^3^ to build the CURB-65L.Fig. 2

4. Discussion {#s0080}
=============

Our study revealed a surprising finding: 52.8% of the patients with CAP showed lymphopenia at hospital admission (\< 1000 lymphocytes/mm^3^) ([@bb0145]), in the absence of antecedents of immunosuppression. Re-examining the data of another large cohort from Marrie and Wu, including 3043 hospitalized patients with CAP and no antecedents of immunosuppression ([@bb0105]), a similar prevalence of lymphopenia was observed at hospital admission (48.4%). In our view, the high prevalence and relevance of lymphopenia in CAP has not been sufficiently considered by the medical community. Lymphopenia could be a cause or a consequence of CAP. Impaired production or increased apoptosis of lymphocytes caused by the presence of chronic diseases or critical illness ([@bb0110]), enhanced adhesion to the vascular endothelium, or massive migration of these cells to the lungs could explain the presence of lymphopenia in some patients with this disease.

Interestingly, we identified a sub-group of lymphopenic patients, those with lymphocyte counts below 724 lymphocytes/mm^3^, which presented a significantly higher risk of 30-day mortality. This subgroup, which represented 33.5% of the patients in the derivation cohort and 35.6% in the validation cohort, accounted for an increased proportion of critically ill patients and of those who developed complications (Supplementary files 2 and 3).

In the work from Marrie and Wu, a lymphocyte count \< 1000 cell/mm^3^ was associated with early but not with late mortality. Nonetheless, there are a number of important differences between this work and ours. The most important one is that Marrie and Wu excluded patients with leukocyte counts \< 1000 cells/mm^3^ and those with critical illness. In addition, they did not evaluate cut-off values below 1000 lymphocytes/mm^3^. Finally, they studied hospital mortality, not mortality at 30-days post-admission as we did.

Early identification of patients at risk of death is a crucial step in the clinical management of CAP ([@bb0005]). In this regard, it was particularly interesting to identify the outcomes corresponding to \< 724 lymphocytes/mm^3^. Our results demonstrate that the new CURB-65L score, which considers the presence of lymphopenia below 724 lymphocytes/mm^3^, outperformed the CURB-65 in the detection of non-survivors. This new CURB-65L score could help to recognize early those CAP patients at risk of a poor outcome. Prompt identification of these patients could contribute to an improvement of their prognosis, because they might benefit from more aggressive treatment strategies. In this regard, evaluation of lymphocyte counts is an inexpensive, widely available test in clinical settings worldwide.

Our results also suggest that lymphocyte counts should be taken into consideration as a potential confusion factor in the design and analysis of future clinical trials evaluating drugs or interventions for the treatment of CAP, because they influence prognosis. In addition, our findings suggest that patients with low lymphocyte counts could be in need of new therapeutic approaches, since the multivariate analysis demonstrated that the presence of low lymphocyte counts conferred an increased risk of mortality independently of receiving an appropriate antibiotic treatment and intensive care. Because of this, adjunctive therapy with drugs inducing expansion of lymphocyte counts or modulating the function of these cells ([@bb0060]; [@bb0130]; [@bb0135]) could represent an option for these patients to be explored in future clinical trials.

Finally, our results showed that neutrophil counts were not associated with mortality risk in patients with CAP and no prior immunosupression, raising doubts for the potential role of drugs aimed to expand neutrophils in this kind of patients. In fact, a systematic review from Cheng et al. in 2007 concluded that the use of G-CSF as an adjunct to antibiotics was not associated with improved 28-day mortality ([@bb0045]). Therefore, the absence of any significant association between neutrophil counts with mortality suggests that the potential value of the neutrophil to lymphocyte ratio as biomarker of mortality in CAP with no immunosupression should be carefully re-evaluated. Additionally, our work presents evidence that CRP is not a biomarker of 30-day mortality in these patients.

A limitation of our study was its retrospective nature. This precluded using potential confusion factors such as body mass index, nutritional intake markers (albumin or pre-albumin) as adjusting variables for lymphocyte counts in the multivariate analysis. Our study lacked data on lymphocyte subsets. The specific impact of CD4, CD8 T cells, B and NK lymphocytes on mortality should be studied in future prospective studies, as well as that of T-regulatory cells (a specific subset of CD4 + T cells with the role of suppressing potentially deleterious activities of T-helper cells). In addition, the identified cut-off values for total lymphocyte counts should be confirmed and validated in future prospective studies, comparing their prognostic efficacy against that of other emerging markers such as Proadrenomedullin.

In conclusion, lymphocyte counts are an independent biomarker of mortality in hospitalized patients with CAP and no immunosuppression. Patients with lymphopenic CAP (L-CAP) with lymphocyte counts \< 724 lymphocytes/mm^3^ constitute a particular immunological phenotype of the disease involving one-third of the patients which is associated with a 2-fold increase in the risk of mortality at 30 days post hospital admission. Using the CURB-65L could help to better detect patients with poor outcomes. In consequence, assessing lymphocyte counts at hospital admission could contribute to personalized clinical management and treatment in CAP.
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